Zum Hauptinhalt springen
| Hans-Günter Meyer-Thompson | Wechselwirkungen mit Substitutionsmitteln

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route.   

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route. 

Kharidia, J., Howgate, E.M., Laffont, C.M., Liu, Y. and Young, M.A. (2021), 

Clinical Pharmacology in Drug Development. doi.org/10.1002/cpdd.934

https://accp1.onlinelibrary.wiley.com/doi/10.1002/cpdd.934